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Metformin and Vitamin B12 Deficiency: Consequences and 
Patient Monitoring
Kathryn Dietz, RN, PA-S
Department of Physician Assistant Studies, University of North Dakota School of Medicine & Health Sciences
Grand Forks, ND  58202-9037
Abstract
Introduction
 From 1980 through 2014, the number of people diagnosed with      
diabetes mellitus has increased from 5.5 to 22 million (Centers 
for Disease Control and Prevention, 2014).  Of these, 90-95% 
have type 2 diabetes mellitus. 
 Most global guidelines recommend starting metformin in 
patients with no contraindications at the time of diagnosis due to 
its efficacy, safety, and cost.
 There have been numerous studies that have suggested a 
relationship between metformin use and decreased vitamin B12 
levels at a rate of 5.8-22.6% (de Groot-Kamphius et al., 2013). 
 While not fully understood, it is hypothesized that it could be 
occurring due to an impaired calcium dependent absorption of 
intrinsic factor and vitamin B12 in the ileum, an altered motility 
of the small intestine, a decrease in the acidity of the stomach, 
or an alteration in the normal flora of the gut (Kibridge & 
Mwebaze, 2013).  
 The purpose of this scholarly project is to establish a link 
between metformin use in type 2 diabetics and vitamin B12 
deficiency, explore the consequences of such a deficiency, and 
make recommendations as to who should be screened.
Research Questions
Literature Review Applicability to Clinical 
Practice
Discussion
The incidence of type 2 diabetes has been increasing at a rapid 
rate in the United States.
Metformin is recommended as the first line treatment to be 
started at the time of diagnosis in all patients without 
contraindications and has been associated with vitamin B12 
deficiency.
There are currently no clinical guidelines for the routine 
monitoring of B12 levels in this population.  
The purpose of this scholarly project is to determine if there are 
consequences of this deficiency and to make recommendations 
for screening patients.  
 It includes current research that focuses on the pathophysiology 
of a B12 deficiency, the prevalence and consequences of such a 
deficiency, and practices in monitoring patients for it. 
While many type 2 diabetics treated with metformin will develop 
a vitamin B12 deficiency, there may not be any consequences of 
this deficiency.  
More research is needed before universal guidelines can be 
established.  At this point in time, monitoring B12 levels should 
be a decision based on individual patient’s risk factors and 
symptoms.
 In adult patients with type 2 diabetes taking metformin, does a 
vitamin B12 deficiency cause adverse effects?  
 In this same population, should routine screening for a vitamin 
B12 deficiency be performed?
Physiologic Role of Vitamin B12 and Pathophysiology of a 
Deficiency
Functions:  
 Necessary for the methylation of homocysteine to 
methionine, which is activated into S-adenosyl-methionine 
and gives a methyl group to methyl acceptors such as 
myelin, neurotransmitters, and membrane phospholipids  
 Necessary for the conversion of methylmalonyl coenzyme A 
(CoA) to succinyl CoA which is involved in the synthesis of 
neuronal membranes  
 Required for  DNA synthesis, hematopoiesis, and cellular 
repair
Vitamin B12 Deficiency:
 Hyperhomocysteinemia which has a damaging effect on 
vascular endothelium and neurons
 An increase in methylmalonic acid (MMA) leading to a 
defective synthesis of fatty acids in neuronal membranes  
 Fatigue, depression, impaired cognition 
 Macrocytic anemia 
 Glossitis, stomatitis and malabsorption 
 Demyelination, degeneration, and death of axons 
manifesting as peripheral and/or autonomic neuropathy, 
delirium, dementia, or a subacute degeneration of the spinal 
cord 
(Kibridge & Mwebaze, 2013)
Metformin and Vitamin B12 Deficiency
 A meta-analysis performed by Niafar, et al. (2015) found that 
metformin treated groups had lower vitamin B12 levels 
(p<0.00001) as well as a higher incidence of vitamin B12 
deficiency (OR 2.45, 95% CI 1.74-3.44, p<0.00001).
 De Jager, et al. (2010) found the decrease in B12 levels to be 
progressive over time and homocysteine levels increased as 
B12 levels decreased.
 Using data from the Diabetes Prevention Program Outcomes 
Study, Aroda et al. (2016) found the only statistically significant 
predictor of vitamin B12 deficiency was the total years of 
exposure to metformin.
 Beulens et. al (2015) found higher daily doses (p<0.001) and 
higher cumulative doses (p<0.022) were associated with lower 
vitamin B12 and holotranscobalamin levels.
 Ko et al. (2014) found those taking metformin in larger doses 
(>1,000 mg/day) and for a longer duration (>4 years) had a 
greater prevalence of vitamin B12 deficiency (p<0.001).
Diagnostic studies that Assess for a Vitamin B12 
Deficiency
 No gold standard
 Serum B12 levels: recently ingested B12; does not detect 
deficiency at tissue level (Pagana & Pagana, 2014); not very 
specific or sensitive (Salwen, 2017)
 Homocysteine: can elevate before vitamin B12 levels are 
abnormal (Pagana & Pagana, 2014)
 Methylmalonic acid (MMA): measured in urine or serum; 
elevation reveals a more longstanding deficiency (Pagana & 
Pagana, 2014)
 Holotranscobalamin: protein that binds up to 25% of circulating 
B12 and delivers it to the tissues; newer method hypothesized 
to be more sensitive in determining a deficiency at the cellular 
level (Beulens, et al., 2015).
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Statement of the Problem
 While the link between metformin and decreased vitamin B12 
levels has been well established in literature, there are no 
clinical guidelines addressing routine evaluation for this 
condition in type 2 diabetics taking this medication.  
 In addition, the effects of such a deficiency in this patient 
population has not been well established. 
References
Patients who are already at risk for a deficiency, such as those 
who are on long term PPIs, abuse alcohol, vegetarians, or are 
malnourished, should be monitored more closely for symptoms 
of a B12 deficiency.
For those patients not already at a risk for a deficiency, assess 
for symptoms of a deficiency prior to initiation of the medication 
as well as at regular follow up visits.
Consider a B12 deficiency in the differential diagnosis when 
symptoms such as peripheral neuropathy, anemia, and 
cardiovascular disease present rather than attributing these 
symptoms to the diabetes.  
Vitamin B12 is water soluble and the excess is excreted in the 
urine so there is little risk of supplementing with B12 in patients 
with adequate renal function even if they are not deficient.
Effects of a Metformin Induced Vitamin B12 
Deficiency on Patients
Adaikalakotswari, et al. (2014) found triglycerides and 
cholesterol/HDL ratios were inversely related to vitamin 
B12 levels but did not find a relationship between B12 
levels and other diabetic co-morbidities such as 
retinopathy, neuropathy, nephropathy, cerebrovascular 
accident, and peripheral vascular disease.
Hansen, et al. (2016) found vitamin B12 levels to be 
inversely related to cardiac autonomic neuropathy.
Aroda, et al. (2016) found that homocysteine levels were 
increased in those with low or borderline low vitamin B12 
levels.  At year 9 of the study, anemia in the metformin 
group was slightly increased in those with lower B12 levels 
but was not significant (p=0.25).
Chen, et al. (2012) used multiple methods to assess for 
neuropathy and were unable to find a significant 
relationship between peripheral neuropathy and vitamin 
B12 levels. 
Singh, et al. (2013) found the duration of metformin use to 
be positively related to neuropathy score (95% CI 0.35-
0.65, p<0.001).
Current Vitamin B12 Monitoring in Type 2 Diabetics 
taking Metformin
Pierce, Chung, & Black (2012) looked at subjects taking 
metformin.  Only 40% of the total subjects had a vitamin 
B12 measured and 46% of patients who had been on high 
dose metformin greater than 10 years had never had one 
assessed. 29% with newly diagnosed anemia and 42% 
with newly documented neuropathy did not have a vitamin 
B12 level measured.
 Farland, et al (2015) found those with symptoms or a 
diagnosis of macrocytic anemia or peripheral neuropathy 
were more likely to have a vitamin B12 level measured 
than those in the control group (OR 5.83, 95% CI 3.47-
9.77, p<0.001), but it was only 48.3% of these patients.  
Symptoms of B12 deficiency are similar to type 2 diabetes 
complications.
 Future studies considering the effect of vitamin B12 
deficiency on type 2 diabetics without considering the use 
of metformin would be beneficial.
Conflicting results in regards to the predictors for a 
deficiency to occur, such as duration of treatment, size of 
dose, and cumulative doses have been observed.
Diet, other comorbidities, or medications can also 
contribute to a deficiency.
Unless the prevalence of a metformin induced vitamin B12 
deficiency is defined more clearly or stronger evidence of 
consequences is found, routine screening of all diabetics 
may not be warranted.
Screening should be considered in those patients who are 
taking higher doses of metformin (>1000 mg/day) or for 
longer durations (>4 years).
Vitamin B12 status should be assessed if symptoms of a 
deficiency are evident.
Screening is not recommended to be performed yearly as 
the stores in the liver can last anywhere from 3 to 6 years. 
